GLP · Company research
Global Partners LP (GLP): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableEnergy
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Global Partners(GLP) Stock Options Chain | Quotes & News - Moomoo | Global Partners(GLP) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 17, 2026 | neutral | 0 | 0.6 |
| A $500M revolver stays intact as Global Partners (GLP) pushes back its credit maturity. - Stock Titan | A $500M revolver stays intact as Global Partners (GLP) pushes back its credit maturity. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| 3 Stocks Retail Investors Are Watching In Oral GLP 1 Weight Loss Drugs - Simply Wall Street | 3 Stocks Retail Investors Are Watching In Oral GLP 1 Weight Loss Drugs Simply Wall Street | View source ↗ | Simply Wall Street | Oct 16, 2026 | neutral | 0 | 0.6 |
| The Oral GLP-1 Tracker: Foundayo, Wegovy pill undergo minor fluctuations - Fierce Pharma | The Oral GLP-1 Tracker: Foundayo, Wegovy pill undergo minor fluctuations Fierce Pharma | View source ↗ | Fierce Pharma | Oct 16, 2026 | neutral | 0 | 0.6 |
| Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use - The American Journal of Managed Care | Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use The American Journal of Managed Care | View source ↗ | The American Journal of Managed Care | Oct 15, 2026 | neutral | 0 | 0.6 |
| Ultragenyx’s second PRV sale; Biomea’s oral GLP-1 data leads to stock slump - Endpoints News | Ultragenyx’s second PRV sale; Biomea’s oral GLP-1 data leads to stock slump Endpoints News | View source ↗ | Endpoints News | Oct 14, 2026 | neutral | 0 | 0.6 |
| KeyBanc reiterates Planet Fitness stock rating on GLP-1 tailwind - Investing.com | KeyBanc reiterates Planet Fitness stock rating on GLP-1 tailwind Investing.com | View source ↗ | Investing.com | Oct 13, 2026 | neutral | 0 | 0.6 |
| When available, cheaper options saved an average $2,790 a year per drug. - Stock Titan | When available, cheaper options saved an average $2,790 a year per drug. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| DataMeds AI (MEDS) Stock Surges On Helomics Deal And GLP-1 App Momentum - Timothy Sykes | DataMeds AI (MEDS) Stock Surges On Helomics Deal And GLP-1 App Momentum Timothy Sykes | View source ↗ | Timothy Sykes | Oct 12, 2026 | neutral | 0 | 0.6 |
| As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool | As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze The Motley Fool | View source ↗ | The Motley Fool | Oct 11, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits | VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t Stocktwits | View source ↗ | Stocktwits | Oct 10, 2026 | neutral | 0 | 0.6 |
| Novo Nordisk (NVO) Stock May Trade Below Fair Value After GLP 1 Expansion Plans - Simply Wall Street | Novo Nordisk (NVO) Stock May Trade Below Fair Value After GLP 1 Expansion Plans Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Could Zacks’ Spotlight on GLP’s Expansion Reveal a Shift in Global Partners’ Valuation Story? - Yahoo Finance | Could Zacks’ Spotlight on GLP’s Expansion Reveal a Shift in Global Partners’ Valuation Story? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Global Partners (GLP) Gains Attention As Expansion Narrative Meets A Fully Valued View - Yahoo Finance | Global Partners (GLP) Gains Attention As Expansion Narrative Meets A Fully Valued View Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Zacks Industry Outlook Western Midstream, Global Partners and NGL Energy Partners | The Oil and Gas - Refining & Marketing MLP industry is well-positioned with a Zacks Industry Rank of #40 (top 16%), supported by diversified business models, stronger balance sheets, and improving earnings expectations. The industry has outperformed the S&P 500 (46.2% vs 16.2% over the past year) and trades at a reasonable 12.25X EV/EBITDA. Three stocks highlighted are Western Midstream Partners (Rank #1), Global Partners (Rank #2), and NGL Energy Partners (Rank #3), each benefiting from fee-based contracts, integrated operations, and long-term commitments. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Zacks Industry Outlook Western Midstream, Global Partners and NGL Energy Partners | The Oil and Gas - Refining & Marketing MLP industry is well-positioned with a Zacks Industry Rank of #40 (top 16%), supported by diversified business models, stronger balance sheets, and improving earnings expectations. The industry has outperformed the S&P 500 (46.2% vs 16.2% over the past year) and trades at a reasonable 12.25X EV/EBITDA. Three stocks highlighted are Western Midstream Partners (Rank #1), Global Partners (Rank #2), and NGL Energy Partners (Rank #3), each benefiting from fee-based contracts, integrated operations, and long-term commitments. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| An ETF adviser reports voting power over 6.05M common units of Global Partners (GLP). - Stock Titan | An ETF adviser reports voting power over 6.05M common units of Global Partners (GLP). Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Eli Lilly: Buy The GLP-1 Growth Premium - Seeking Alpha | Eli Lilly: Buy The GLP-1 Growth Premium Seeking Alpha | View source ↗ | Seeking Alpha | Oct 7, 2026 | neutral | 0 | 0.6 |
| A patent filing proposes cells to make weight-loss medicine inside the body - Stock Titan | A patent filing proposes cells to make weight-loss medicine inside the body Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity? - The Motley Fool | Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity? The Motley Fool | View source ↗ | The Motley Fool | Oct 7, 2026 | neutral | 0 | 0.6 |
| Hims & Hers Health Stock Forecast | FDA GLP-1 Warning - Capital.com | Hims & Hers Health Stock Forecast | FDA GLP-1 Warning Capital.com | View source ↗ | Capital.com | Oct 6, 2026 | neutral | 0 | 0.6 |
| Should Value Investors Buy Global Partners (GLP) Stock? | Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. The article highlights Global Partners (GLP) as a value stock pick with a Zacks Rank #2 (Buy) rating, featuring attractive valuation metrics including a P/B ratio of 2.73 and P/CF ratio of 6.78. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Global Partners (GLP) Stock? | Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. The article highlights Global Partners (GLP) as a value stock pick with a Zacks Rank #2 (Buy) rating, featuring attractive valuation metrics including a P/B ratio of 2.73 and P/CF ratio of 6.78. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Global Partners (GLP) Stock? - Yahoo Finance | Should Value Investors Buy Global Partners (GLP) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s - CNBC | Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s CNBC | View source ↗ | CNBC | Sep 25, 2026 | neutral | 0 | 0.6 |
| Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors - Fierce Pharma | Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors Fierce Pharma | View source ↗ | Fierce Pharma | Sep 23, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.